Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
about
Short-term effects of topical levobunolol on the human retinal circulationRecent advances in pharmacotherapy of glaucomaThe evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension.Changing therapeutic paradigms in glaucoma management.Does the renin-angiotensin system also regulate intra-ocular pressure?Metabolism of ophthalmic timolol: new aspects of an old drug.Latanoprost/timolol fixed combination for the treatment of glaucoma.Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.Beta blockers and the elderly with glaucoma: are we adding insult to injury?Comparison of the ocular beta-blockers.Evaluation of skin permeation of β-blockers for topical drug delivery.Effects of selective serotonin reuptake inhibitors on timolol metabolism in human liver microsomes and cryo-preserved hepatocytes.Open-angle glaucoma: therapeutically targeting the extracellular matrix of the conventional outflow pathway.Predicted Biological Activity of Purchasable Chemical Space.A Rapid Extraction Method to Quantify Drug Uptake in Contact Lenses.Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel
P2860
Q28254938-205A4780-38D2-4D89-B922-EC4BD998AA0EQ33521178-7B30F32E-E92A-4EDC-9A25-8FD1DC936A07Q34182124-F133CC35-0453-40C7-8A01-B08C2A2AE90FQ35753429-34D3A382-5600-471B-8375-2EBFBC978D8DQ36181220-6D28A680-93E4-44FF-BDE1-4C55C925C224Q37374642-EB8CF98D-8D19-42D4-BBEB-FC5F0A0750ADQ37850837-48003FC1-437F-4E22-B017-FCB8DFD78EEFQ38117401-28810321-22F2-4DFB-8EDF-92CF70E81888Q38244537-C2EAC440-5B2B-4DDF-8683-E02FB05577DAQ38963936-98249B8B-BECD-426A-8010-946BFB7A4F8BQ39712170-E7AEE3CC-D237-431C-956B-5EFECF268605Q41084276-B89B0307-2B63-4DD3-A181-638189DFC2ECQ42910405-BAA9AB73-95F1-4FF1-A07A-DBDACA088CBAQ43242688-566E0201-85DF-4033-935E-FC99BFC2D6E3Q45872509-4F4B6322-105A-48CD-9AE7-2F7455C1112CQ47385721-922B0AFE-5DBD-47DC-B01D-CF3CA5999F38Q52620262-5B1BA63E-0691-4F13-A8AC-1676FD979074Q57417600-D0328B5F-128A-4A55-8B68-CE4B662EDB56
P2860
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
description
1992 nî lūn-bûn
@nan
1992 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@ast
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@en
type
label
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@ast
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@en
prefLabel
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@ast
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@en
P1433
P1476
Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects.
@en
P2093
P304
P356
10.2165/00002512-199202030-00005
P577
1992-05-01T00:00:00Z
P6179
1044706035